Brittany Meiling

Nasdaq darling and Shanghai hotshot Zai Lab is ditching one of its late-stage drug programs after bombing a Phase IIa trial. The company said Friday that its topical product ZL ...

Let’s be honest, the market for weight loss drugs has mostly been bust. While the industry has moved on from the fen-phen fiasco of decades past, newer diet pills like ...

Five years ago, Roche touted a clinical success for one of its mid-stage cardio programs, reporting the investigational med showed promise in reducing heart damage. Promising, they said, but apparently ...

For years now, psychedelic scientists have been telling us that tripping on magic mushrooms might “reboot” the brain, clearing out negative thought networks that might contribute to depression. Now, it ...

It’s official. Mallinckrodt’s newly-acquired jaundice drug just got kicked back by the FDA. The England-based drugmaker was expecting ominous news after the agency’s advisory committee voted strongly against the drug� ...

A backwards glance at trial data — and a reshuffling of the patients involved — has reverted failure to optimism for Tonix Pharmaceuticals. At least that’s what company execs are rooting for ...

It’s been a year of great strides in gene therapy, with Spark’s Luxturna earning the first US regulatory approval in the field for inherited blindness. Now, researchers at University of ...

Novo Nordisk is building a blockbuster case for its diabetes drug semaglutide, trotting out Phase IIIa trial results Monday that show its new pill version of the drug worked better ...

When AstraZeneca spun out its struggling antibiotics unit a few years back, the tech — and a much smaller team — was deposited into a company called Entasis. Now, that upstart has ...

When it comes to determining coverage for expensive — but potentially lifesaving — CAR-T therapies, CMS doesn’t have to roll over and let drugmakers dominate the conversation. The agency, instead, should leverage ...

Eisai’s star cancer drug Lenvima — the subject of a recent $300 million pact with Merck — just got the green light from regulators to treat a new indication in liver cancer ...

After taking off the past 7 months to travel the world and spend time with family, former Foundation Medicine exec Steve Kafka is joining the startup foundry Third Rock Venture ...

Scientists at Memorial Sloan Kettering have engineered a hybrid cancer therapy that might just bring two of hottest areas of oncology science together in one package: CAR-T and checkpoint inhibitors ...

An investor group based in the Midwest is tapping the booming biotech scene in China to launch a new investment vehicle for traders interested in promising Chinese ventures. Loncar Investments ...

The billionaire-backed startup Juvenescence — best known for its big plans to tackle aging — is spinning out a new company to develop research out of the Buck Institute for Research ...

After walking away from a long career in Big Pharma last year — only to bail from his startup of choice only 10 months later — ex-Pfizer exec Geno Germano is back ...

Allergan {$AGN} has recruited top cancer executive Charles Hugh-Jones, the guy who’s been leading Pfizer Oncology as CMO, to serve as the pharma giant’s new senior vice president and chief ...

→ The US congressman who was charged with insider trading on a biotech stock last week has suspended his campaign for re-election. New York GOP Rep. Chris Collins, the first ...

After yanking its own neuroscience efforts — and retreating from the failure-strewn battleground of brain science — Pfizer is pedaling back to the beginning in this field. The pharma giant is funding ...

→ Just a couple days after announcing some mixed pipeline updates that yo-yoed the stock, gene therapy company RegenXBio {$RGNX} is trotting out news of a stock offering totaling ...